The Center for Biosimilars Staff

During the second day of the 36th Annual J.P. Morgan Healthcare Conference, Amgen and Mylan highlighted their progress with biosimilar therapies, while Roche and Sanofi focused on progress with innovator products and combinations that may help insulate them from biosimilar and follow-on competition.

On the first day of the 36th Annual J.P. Morgan Healthcare Conference, biosimilar developers Coherus, Pfizer, and Teva all laid out their strategies for the year ahead.

Mumbai-based Glenmark Pharmaceuticals launched a biosimilar adalimumb, Adaly, in the Indian marketplace this week, following Hetero's launch of Mabura.

The Center for Biosimilars recaps the most-read articles of 2017.

The Center for Biosimilars recounts 4 of the top legal developments in the biosimilars space during 2017.

2017 brought a number of notable guests to The Center for Biosimilars®. Here are the most-watched interviews of the year.

The United States now has 9 FDA-approved biosimilars. Our latest infographic breaks down what you need to know about these products.

The Center for Biosimilars recaps the the top 5 articles for the week of December 18, 2017.

The Center for Biosimilars® recaps the top 5 articles for the week of December 11.

Mark Fendrick, MD, discusses the role that biosimilars will play in value-based insurance design (VBID).

Our latest infographic provides 3 key takeaways from the American Society of Hematology's (ASH) 59th Annual Meeting and Exposition.

The Center for Biosimilars recaps the top 5 articles for the week of December 4.

USV has announced that the European Medicines Agency (EMA) has accepted for review its application for a proposed pegfilgrastim biosimilar.

A new study, conducted by Linglong Zou, PhD, and colleagues, evaluates the immunogenicity of tbo-filgrastim in patients receiving chemotherapy for solid and hematologic malignancies.

Lucentis (ranibizumab) faces oncoming competition from 4 companies that are developing proposed biosimilars.

The Center for Biosimilars recaps the top 5 articles for the week of November 27.

Because biosimilars are relatively new to the United States, drug makers pursuing FDA approval for biosimilars seek additional information about the kinds and quantities of evidence that the agency uses to approve these therapies.

This week, the Supreme Court of the United States heard oral arguments in Oil States Energy Services, LLC v Greene’s Energy Group, LLC, a case that asks the court to decide whether inter partes review (IPR) is constitutional.

German drug maker Formycon released its third quarter financial results on Monday, and reported that it plans to launch its biosimilar ranibizumab candidate, FYB201, in the United States in 2020.

Biologics are increasingly used in the treatment of inflammatory bowel disease (IBD), but real-world data quantifying the costs of these therapies have been lacking. A new study, published in Alimentary Pharmacology and Therapeutics, sought to determine trends in costs and relative market share of IBD therapies in the United States over the past 9 years.

Our latest infographic covers 4 key takeaways from the SMi Biosimilars North America 2017 conference.

The Center for Biosimilars recaps the top 5 stories in biosimilars news for the week of November 20.

Results of a new national survey conducted by the Alliance for Safe Biologic Medicines (ASBM) shows that Canadian physicians support the use of distinguishable names for biologic therapies, including biosimilars,

Low levels of competition among drug makers can lead to product shortages and increased generic drug prices, and a recently published study in Global Health suggests that mergers and acquisitions, which reduce the number of players in the pharmaceutical field, should be closely monitored by regulatory authorities.

The American College of Rheumatology (ACR) has voiced its approval of CMS’ attempts to lower the cost of drugs under Medicare Part D, but also called on the organization to allow more rheumatologists, including those in small practices, to take part in alternative payment models (APMs).

Amsterdam, Netherlands, has won its bid to become the new home of the European Medicines Agency.

Four recent studies investigated the proposed etanercept biosimilars SB4, LBEC0101, CHS-0214, and GP2015.

The Center for Biosimilars® recaps the top 5 stories in biosimilars news for the week of November 13.

A new CMS proposed rule seeks to encourage the use of lower-cost biosimilars instead of reference biologics under Medicare Part D. The proposed rule would modify the definition of generic drugs—for the purposes of non–low-income-subsidy (LIS) catastrophic and LIS cost-sharing—to include biosimilar therapies.

The past week has seen the resolution of 2 high-profile biosimilar patent infringement cases. In the first, a district court’s ruling was upheld, and in the second, a reference drug sponsor agreed to drop its infringement claims—with prejudice—against a biosimilar developer.